LUMA Vision has secured another FDA clearance expanding VERAFEYE ahead of a planned early-2027 United States launch. The system combines intracardiac ultrasound, live 3D anatomical reconstruction, catheter tracking and ablation guidance, challenging the electrophysiology lab’s traditional reliance on several separate imaging and navigation tools.
Vitestro’s Aletta has become the first standalone autonomous robotic blood-draw device authorized by the FDA. With one trained supervisor permitted to oversee as many as three systems, the technology could address workforce constraints and standardize venipuncture, but throughput, cost, difficult-vein performance and patient acceptance will determine whether robotics actually changes laboratory medicine.
The FDA has granted Breakthrough Therapy Designation to UCB’s CIMZIA for high-risk pregnant women with antiphospholipid syndrome after Phase 2 evidence suggested that adding TNF inhibition to standard aspirin and heparin could reduce severe placenta-mediated complications. The programme challenges a long-standing assumption that preventing thrombosis alone is sufficient to manage obstetric APS.
AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.
Revolution Medicines’ RASONQUE has become the first broad RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma after Phase 3 data showed a 60% reduction in the risk of death compared with chemotherapy. The approval matters well beyond one cancer because it tests whether RAS, long regarded as one of oncology’s hardest targets, can support an entire
AstraZeneca has secured FDA accelerated approval for Etcamah after SERENA-6 showed that switching therapy when an ESR1 mutation emerged in circulating tumour DNA sharply delayed disease progression. Days later, however, the broader SERENA-4 first-line trial missed its primary endpoint, creating an unusually clear demonstration that patient selection and treatment timing may matter as much as
Abbott Laboratories has received FDA approval for TactiFlex Duo, a focal ablation catheter capable of delivering both pulsed-field and radiofrequency energy. The system enters a rapidly expanding pulsed-field ablation market with a different proposition: instead of replacing thermal ablation entirely, it lets electrophysiologists choose between energy types during the same procedure.
Emboline’s Emboliner has received FDA 510(k) clearance after a randomized head-to-head trial showed similar 30-day clinical outcomes to Boston Scientific’s Sentinel but substantially greater debris capture and higher deployment success. The device now faces a commercial question its pivotal trial could not fully answer: whether protecting more of the circulation ultimately improves patient outcomes.
Nanoscope Therapeutics has moved MOGENRY into formal FDA review for severe vision loss caused by retinitis pigmentosa. The therapy’s optogenetic strategy is unusual because it attempts to restore light sensitivity in surviving retinal cells regardless of the patient’s underlying mutation, potentially expanding gene therapy beyond one-gene-one-drug models.
Nutromics has received FDA Breakthrough Device Designation for a wearable patch designed to monitor vancomycin continuously rather than through intermittent laboratory blood draws. Human feasibility data support the concept, but sensor durability, accuracy in critically ill patients and integration into dosing decisions remain the real commercial hurdles.